N@N

ALEXION PHARMACEUTICALS INC (NASDAQ:ALXN), Up By 7.51% ($4.46) After BUYINS.NET SqueezeTrigger Report Released on Tuesday, Sept

^{Published on 2011-09-15 13:21:53 - WOPRAI}
 

September 15, 2011 / M2 PRESSWIRE / BUYINS.NET, www.buyins.net , a leading provider of Regulation SHO compliance monitoring, short sale trading statistics and market integrity surveillance, released a report on Tuesday, September 13th 2011 at 13:16:00 PDT stating that ALEXION PHARMACEUTICALS INC (NASDAQ:ALXN) was expected to be Up After it crossed above its SqueezeTrigger Price of 59.41 on Tuesday, September 13th 2011. Click here to view the BUYINS.NET report: http://www.buyins.net/releases/?sym=alxn&id=193825

From August 2009 to August 2011, an aggregate amount of 126510430 shares of ALXN have been shorted for a total dollar value of $7464115370. The ALXN SqueezeTrigger price of $59.41 is the volume weighted average price that all shorts are short in shares of ALXN. There is still approximately $347,674,348 of potential short covering in shares of ALXN.

SqueezeTrigger.com has built a massive database that collects, analyzes and publishes a proprietary SqueezeTrigger Price for each stock that has been shorted. The data has then been integrated into an automated trading platform which can be used to connect to a live online broker and automate your trading of short squeeze events. It is extremely powerful with lightening fast execution at a very low price. Both the trading software and SqueezeTrigger data feed are available at http://www.squeezetrigger.com .

ALEXION PHARMACEUTICALS INC (NASDAQ:ALXN) - Alexion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of biologic therapeutic products in the United States, Europe, Latin America, Japan, and the Asia Pacific. It focuses on products for severe and life-threatening disease states, including hematologic, kidney, and neurologic diseases; transplant rejection; cancer; and autoimmune disorders. The company markets Soliris (eculizumab) for the treatment of patients with paroxysmal nocturnal hemoglobinuria, a blood disorder. It also conducts various Phase II clinical trials on Soliris for the treatment of atypical hemolytic uremic syndrome, MPGN II dense deposit disease, presensitized renal transplant, myasthenia gravis, neuromyelitis optica, multifocal motor neuropathy, and dry age-related macular degeneration. In addition, the company conducts preclinical studies on Soliris for the treatment of presensitized cardiac transplant, cold agglutinin disease, and catastrophic antiphospholipid syndrome. Further, its clinical programs include Samalizumab, which is in Phase I/II clinical trials for the treatment of chronic lymphocytic leukemia and multiple myeloma. Alexion Pharmaceuticals serves specialty distributors and specialty pharmacies, which supply physician office clinics, hospital outpatient clinics, infusion clinics, or home health care providers; government agencies; and hospitals, hospital buying groups, pharmacies, other healthcare providers, and distributors. The company was founded in 1992 and is headquartered in Cheshire, Connecticut.

The SqueezeTrigger database of approximately 1 billion short sale transactions goes back to January 1, 2005 and calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005 because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like SqueezeTrigger.com to access the data. Total Short Interest is the number of shares shorted but not yet covered, and is different from total short volume. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.squeezetrigger.com

About BUYINS.NET

BUYINS.NET, http://www.buyins.net, monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market-maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market-maker surveillance system tracking market makers in all stocks to determine Price Friction and compliance with new "Fair Market-Making Requirements".

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and all Threshold Security Lists daily for which stocks have naked short positions.

INVESTMENTS & TRADING

SqueezeTrigger -- 28 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts next move in stocks.

GATS -- tracks and quantifies known trading strategies.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. [symbol] has not approved the statements made in this release. Please read our report and visit our web site, http://www.buyins.net, for complete risks and disclosures.

Contact: BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net http://www.buyins.net